Outlook Therapeutics, Inc. (OTLK)
0.6299
-0.01
(-1.65%)
USD |
NASDAQ |
Sep 09, 12:39
Outlook Therapeutics Enterprise Value : 127.02M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 127.02M |
| September 04, 2026 | 131.89M |
| September 03, 2026 | 128.62M |
| September 02, 2026 | 124.37M |
| September 01, 2026 | 123.77M |
| August 31, 2026 | 125.70M |
| August 28, 2026 | 127.85M |
| August 27, 2026 | 127.14M |
| August 26, 2026 | 123.81M |
| August 25, 2026 | 126.93M |
| August 24, 2026 | 121.13M |
| August 21, 2026 | 128.28M |
| August 20, 2026 | 133.72M |
| August 19, 2026 | 136.30M |
| August 18, 2026 | 138.16M |
| August 17, 2026 | 132.96M |
| August 14, 2026 | 148.71M |
| August 13, 2026 | 173.48M |
| August 12, 2026 | 213.00M |
| August 11, 2026 | 218.61M |
| August 10, 2026 | 222.35M |
| August 07, 2026 | 198.03M |
| August 06, 2026 | 189.14M |
| August 05, 2026 | 199.90M |
| August 04, 2026 | 186.84M |
| Date | Value |
|---|---|
| August 03, 2026 | 178.01M |
| July 31, 2026 | 189.91M |
| July 30, 2026 | 201.77M |
| July 29, 2026 | 194.29M |
| July 28, 2026 | 176.32M |
| July 27, 2026 | 206.45M |
| July 24, 2026 | 270.06M |
| July 23, 2026 | 254.16M |
| July 22, 2026 | 257.90M |
| July 21, 2026 | 272.87M |
| July 20, 2026 | 265.38M |
| July 17, 2026 | 267.25M |
| July 16, 2026 | 280.35M |
| July 15, 2026 | 299.06M |
| July 14, 2026 | 330.87M |
| July 13, 2026 | 297.19M |
| July 10, 2026 | 300.93M |
| July 09, 2026 | 321.51M |
| July 08, 2026 | 323.38M |
| July 07, 2026 | 280.35M |
| July 06, 2026 | 272.87M |
| July 02, 2026 | 278.48M |
| July 01, 2026 | 282.22M |
| June 30, 2026 | 304.67M |
| June 29, 2026 | 196.24M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Valion Bio, Inc. | 23.36M |
| Agenus, Inc. | 581.29M |
| Amgen, Inc. | 255.86B |
| Anika Therapeutics, Inc. | 268.42M |
| BioCryst Pharmaceuticals, Inc. | 2.798B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -20.32M |
| Revenue (Quarterly) | 0.0087M |
| Total Expenses (Quarterly) | 20.33M |
| EPS Diluted (Quarterly) | -0.1486 |
| Gross Profit Margin (Quarterly) | -254.0% |
| Profit Margin (Quarterly) | -233.6K% |
| Earnings Yield | -179.6% |
| Normalized Earnings Yield | -154.37 |